CoChat
Sign Up
Cited by 44Diabetes and associated disordersT-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research

Evolving antibody therapies for the treatment of type 1 diabetes

Open access
Ke, Qi, Kroger, Charles J., Clark, Matthew, Tisch, Roland M.·2021·Frontiers in Immunology
DOI 10.3389/fimmu.2020.624568PMC PMC7930374
Open this paper in CoChat — free accountOpen PDF

Abstract

Type 1 diabetes (T1D) is widely considered to be a T cell driven autoimmune disease resulting in reduced insulin production due to dysfunction/destruction of pancreatic β cells. Currently, there continues to be a need for immunotherapies that selectively reestablish persistent β cell-specific self-tolerance for the prevention and remission of T1D in the clinic. The utilization of monoclonal antibodies (mAb) is one strategy to target specific immune cell populations inducing autoimmune-driven pathology. Several mAb have proven to be clinically safe and exhibit varying degrees of efficacy in modulating autoimmunity, including T1D. Traditionally, mAb therapies have been used to deplete a targeted cell population regardless of antigenic specificity. However, this treatment strategy can prove detrimental resulting in the loss of acquired protective immunity. Nondepleting mAb have also been applied to modulate the function of immune effector cells. Recent studies have begun to define novel mechanisms associated with mAb-based immunotherapy that alter the function of targeted effector cell pools. These results suggest short course mAb therapies may have persistent effects for regaining and maintaining self-tolerance. Furthermore, the flexibility to manipulate mAb properties permits the development of novel strategies to target multiple antigens and/or deliver therapeutic drugs by a single mAb molecule. Here, we discuss current and potential future therapeutic mAb treatment strategies for T1D, and T cell-mediated autoimmunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.624568

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Teplizumab therapy is a powerful means of delaying the decrease in C-peptide production and can support the maintenance of β-cell function.

    “According to a number of human clinical trials, teplizumab therapy is a powerful means of delaying the decrease in C-peptide production and can support the maintenance of β-cell function (126, 127).”

    From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [126]

    The Anti-CD3 Therapy section reports sustained C-peptide responses and insulin production for two years after teplizumab treatment in newly diagnosed patients. It also says the phase III trials missed their primary endpoints and reduced C-peptide loss appeared in a subset on post-hoc analysis. Those qualifications do not support calling teplizumab a broadly “powerful means” of preserving β-cell function. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Monoclonal antibodies have been shown to be clinically safe and to have varying degrees of efficacy in modulating autoimmunity, including T1D.

    “One tactic to target immune cell populations that cause autoimmune-driven pathology is the use of monoclonal antibodies, which have been shown to be clinically safe and to have varying degrees of efficacy in modulating autoimmunity, including T1D (126).”

    From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [126]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 225

  1. [1]Clark M Kroger CJ Tisch RM. Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response. Front Immunol (2017) 8: 1898. 10.3389/fimmu.2017.01898 29312356 PMC5743904 · DOI
  2. [2]Tisch R McDevitt H. Insulin-dependent diabetes mellitus. Cell (1996) 85(3): 291–7. 10.1016/s0092-8674(00)81106-x 8616883 · DOI
  3. [3]Eisenbarth GS. Type 1 diabetes: molecular, cellular and clinical immunology. Adv Exp Med Biol (2004) 552: 306–10. 15622970
  4. [4]Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev (1994) 15(4): 516–42. 10.1210/edrv-15-4-516 7988484 · DOI
  5. [5]van Belle TL Coppieters KT von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 91(1): 79– 118. 10.1152/physrev.00003.2010 21248163 · DOI · Paper page
  6. [6]Katsarou A Gudbjornsdottir S Rawshani A Dabelea D Bonifacio E Anderson BJ. Type 1 diabetes mellitus. Nat Rev Dis Primers (2017) 3: 17016. 10.1038/nrdp.2017.16 28358037 · DOI · Paper page
  7. [8]von Herrath M Sanda S Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol (2007) 7(12): 988–94. 10.1038/nri2192 17982429 · DOI
  8. [9]Campbell-Thompson M Fu A Kaddis JS Wasserfall C Schatz DA Pugliese A. Insulitis and beta-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes (2016) 65(3): 719–31. 10.2337/db15-0779 PMC4764143 26581594 · DOI
  9. [10]Anderson MS Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 23: 447–85. 10.1146/annurev.immunol.23.021704.115643 15771578 · DOI · Paper page
  10. [11]Driver JP Serreze DV Chen YG. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2011) 33(1): 67– 87. 10.1007/s00281-010-0204-1 20424843 · DOI
  11. [12]Barrett JC Clayton DG Concannon P Akolkar B Cooper JD Erlich HA. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet (2009) 41(6): 703–7. 10.1038/ng.381 PMC2889014 19430480 · DOI · Paper page
  12. [13]Concannon P Rich SS Nepom GT. Genetics of type 1A diabetes. N Engl J Med (2009) 360(16): 1646–54. 10.1056/NEJMra0808284 19369670 · DOI · Paper page
  13. [15]Pociot F Akolkar B Concannon P Erlich HA Julier C Morahan G. Genetics of type 1 diabetes: what’s next? Diabetes (2010) 59(7): 1561–71. 10.2337/db10-0076 PMC2889752 20587799 · DOI
  14. [16]Pociot F McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun (2002) 3(5): 235–49. 10.1038/sj.gene.6363875 12140742 · DOI
  15. [17]Coppieters KT Dotta F Amirian N Campbell PD Kay TW Atkinson MA. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 209(1): 51– 60. 10.1084/jem.20111187 22213807 PMC3260877 · DOI · Paper page
  16. [18]Coppieters KT Roep BO von Herrath MG. Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol (2011) 33(1): 1– 7. 10.1007/s00281-010-0236-6 21170533 · DOI
  17. [19]Atkinson MA von Herrath M Powers AC Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes–considerations for attempts to prevent and reverse the disease. Diabetes Care (2015) 38(6): 979–88. 10.2337/dc15-0144 PMC4439528 25998290 · DOI
  18. [20]Arif S Gibson VB Nguyen V Bingley PJ Todd JA Guy C. beta-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults. Diabetes Med (2017) 34(3): 419–25. 10.1111/dme.13153 27151105 · DOI
  19. [21]Michels AW Landry LG McDaniel KA Yu L Campbell-Thompson M Kwok WW. Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes (2017) 66(3): 722–34. 10.2337/db16-1025 PMC5319719 27920090 · DOI
  20. [22]Kent SC Mannering SI Michels AW Babon JAB. Deciphering the Pathogenesis of Human Type 1 Diabetes (T1D) by Interrogating T Cells from the “Scene of the Crime”. Curr Diabetes Rep (2017) 17(10): 95. 10.1007/s11892-017-0915-y PMC5600889 28864875 · DOI
  21. [23]Heninger AK Eugster A Kuehn D Buettner F Kuhn M Lindner A. A divergent population of autoantigen-responsive CD4+ T cells in infants prior to beta cell autoimmunity. Sci Transl Med (2017) 9(378). 10.1126/scitranslmed.aaf8848 28228602 · DOI
  22. [24]Willcox A Richardson SJ Bone AJ Foulis AK Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol (2009) 155(2): 173–81. 10.1111/j.1365-2249.2008.03860.x PMC2675247 19128359 · DOI · Paper page
  23. [25]Richardson SJ Willcox A Bone AJ Morgan NG Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol (2011) 33(1): 9– 21. 10.1007/s00281-010-0205-0 20424842 · DOI
  24. [26]Babon JA DeNicola ME Blodgett DM Crevecoeur I Buttrick TS Maehr R. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med (2016) 22(12): 1482–7. 10.1038/nm.4203 PMC5140746 27798614 · DOI
  25. [27]Pugliese A. Autoreactive T cells in type 1 diabetes. J Clin Invest (2017) 127(8): 2881–91. 10.1172/JCI94549 PMC5531393 28762987 · DOI
  26. [28]Gomez-Tourino I Arif S Eichmann M Peakman M. T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review. J Autoimmun (2016) 66: 7– 16. 10.1016/j.jaut.2015.08.012 26343335 · DOI
  27. [29]Mallone R Brezar V Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol (2011) 2011: 513210. 10.1155/2011/513210 21785617 PMC3140193 · DOI
  28. [30]Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia (2003) 46(3): 305–21. 10.1007/s00125-003-1089-5 12687328 · DOI
  29. [31]Krishnamurthy B Selck C Chee J Jhala G Kay TW. Analysis of antigen specific T cells in diabetes - Lessons from pre-clinical studies and early clinical trials. J Autoimmun (2016) 71: 35– 43. 10.1016/j.jaut.2016.03.018 27083395 · DOI
  30. [32]Nerup J Platz P Andersen OO Christy M Lyngsoe J Poulsen JE. HL-A antigens and diabetes mellitus. Lancet (1974) 2(7885): 864–6. 10.1016/s0140-6736(74)90930-1 4137711 · DOI · Paper page
  31. [33]Singal DP Blajchman MA. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes (1973) 22(6): 429–32. 10.2337/diab.22.6.429 4541338 · DOI · Paper page
  32. [35]Skog O Korsgren S Melhus A Korsgren O. Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease. Curr Opin Endocrinol Diabetes Obes (2013) 20(2): 118–23. 10.1097/MED.0b013e32835edb89 23422243 · DOI
  33. [36]Yu L Rewers M Gianani R Kawasaki E Zhang Y Verge C. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab (1996) 81(12): 4264–7. 10.1210/jcem.81.12.8954025 8954025 · DOI
  34. [37]Yu L Robles DT Abiru N Kaur P Rewers M Kelemen K. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A (2000) 97(4): 1701–6. 10.1073/pnas.040556697 PMC26499 10677521 · DOI
  35. [38]Simmons KM Michels AW. Type 1 diabetes: A predictable disease. World J Diabetes (2015) 6(3): 380–90. 10.4239/wjd.v6.i3.380 PMC4398895 25897349 · DOI
  36. [39]Chmiel R Giannopoulou EZ Winkler C Achenbach P Ziegler AG Bonifacio E. Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia (2015) 58(2): 411–3. 10.1007/s00125-014-3443-1 25409656 · DOI
  37. [40]Ehlers MR. Strategies for clinical trials in type 1 diabetes. J Autoimmun (2016) 71: 88– 96. 10.1016/j.jaut.2016.03.008 27068279 PMC4903883 · DOI
  38. [42]Serreze DV Chapman HD Varnum DS Hanson MS Reifsnyder PC Richard SD. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J Exp Med (1996) 184(5): 2049–53. 10.1084/jem.184.5.2049 PMC2192892 8920894 · DOI
  39. [43]Serreze DV Fleming SA Chapman HD Richard SD Leiter EH. Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol (1998) 161(8): 3912–8. 9780157
  40. [44]Akashi T Nagafuchi S Anzai K Kondo S Kitamura D Wakana S. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese diabetic mice. Int Immunol (1997) 9(8): 1159–64. 10.1093/intimm/9.8.1159 9263013 · DOI
  41. [45]Ferris ST Carrero JA Unanue ER. Antigen presentation events during the initiation of autoimmune diabetes in the NOD mouse. J Autoimmun (2016) 71: 19– 25. 10.1016/j.jaut.2016.03.007 27021276 PMC4903912 · DOI
  42. [46]Unanue ER Ferris ST Carrero JA. The role of islet antigen presenting cells and the presentation of insulin in the initiation of autoimmune diabetes in the NOD mouse. Immunol Rev (2016) 272(1): 183– 201. 10.1111/imr.12430 27319351 PMC4938008 · DOI
  43. [47]Gagnerault MC Luan JJ Lotton C Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med (2002) 196(3): 369–77. 10.1084/jem.20011353 PMC2193939 12163565 · DOI
  44. [48]Turley S Poirot L Hattori M Benoist C Mathis D. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 198(10): 1527–37. 10.1084/jem.20030966 PMC2194112 14623908 · DOI
  45. [49]Eizirik DL Colli ML Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol (2009) 5(4): 219–26. 10.1038/nrendo.2009.21 19352320 · DOI · Paper page
  46. [50]Shao S He F Yang Y Yuan G Zhang M Yu X. Th17 cells in type 1 diabetes. Cell Immunol (2012) 280(1): 16– 21. 10.1016/j.cellimm.2012.11.001 23246831 · DOI
  47. [51]Kenefeck R Wang CJ Kapadi T Wardzinski L Attridge K Clough LE. Follicular helper T cell signature in type 1 diabetes. J Clin Invest (2015) 125(1): 292– 303. 10.1172/JCI76238 25485678 PMC4382272 · DOI
  48. [52]Walker LS von Herrath M. CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol (2016) 183(1): 16– 29. 10.1111/cei.12672 26102289 PMC4687517 · DOI
  49. [53]Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 29: 621–63. 10.1146/annurev-immunol-031210-101400 21314428 · DOI · Paper page
  50. [54]Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity (2014) 41(4): 529–42. 10.1016/j.immuni.2014.10.004 PMC4223692 25367570 · DOI · Paper page
  51. [55]Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity (2019) 50(5): 1132–48. 10.1016/j.immuni.2019.04.011 PMC6532429 31117010 · DOI · Paper page
  52. [56]Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 3(2): 133–46. 10.1038/nri1001 12563297 · DOI
  53. [57]Arif S Leete P Nguyen V Marks K Nor NM Estorninho M. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes (2014) 63(11): 3835–45. 10.2337/db14-0365 PMC4207393 24939426 · DOI
  54. [58]Arif S Tree TI Astill TP Tremble JM Bishop AJ Dayan CM. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 113(3): 451–63. 10.1172/JCI19585 PMC324541 14755342 · DOI
  55. [59]Emamaullee JA Davis J Merani S Toso C Elliott JF Thiesen A. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 58(6): 1302–11. 10.2337/db08-1113 PMC2682686 19289457 · DOI
  56. [60]Spolski R Kashyap M Robinson C Yu Z Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A (2008) 105(37): 14028–33. 10.1073/pnas.0804358105 PMC2544573 18779574 · DOI
  57. [61]Edner NM Heuts F Thomas N Wang CJ Petersone L Kenefeck R. Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes. Nat Immunol (2020) 21(10): 1244–55. 10.1038/s41590-020-0744-z PMC7610476 32747817 · DOI
  58. [62]Korn T Bettelli E Oukka M Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol (2009) 27: 485– 517. 10.1146/annurev.immunol.021908.132710 19132915 · DOI · Paper page
  59. [63]Cnop M Welsh N Jonas JC Jorns A Lenzen S Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes (2005) 54 Suppl 2: S97– 107. 10.2337/diabetes.54.suppl_2.s97 16306347 · DOI · Paper page
  60. [64]Wilcox NS Rui J Hebrok M Herold KC. Life and death of beta cells in Type 1 diabetes: A comprehensive review. J Autoimmun (2016) 71: 51–8. 10.1016/j.jaut.2016.02.001 PMC4903951 27017348 · DOI
  61. [65]Rotondi M Chiovato L Romagnani S Serio M Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev (2007) 28(5): 492– 520. 10.1210/er.2006-0044 17475924 · DOI
  62. [66]Roep BO Kracht MJ van Lummel M Zaldumbide A. A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes. Curr Opin Immunol (2016) 43: 67– 73. 10.1016/j.coi.2016.09.007 27723537 · DOI
  63. [67]Delong T Wiles TA Baker RL Bradley B Barbour G Reisdorph R. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science (2016) 351(6274): 711–4. 10.1126/science.aad2791 PMC4884646 26912858 · DOI
  64. [68]Gur C Porgador A Elboim M Gazit R Mizrahi S Stern-Ginossar N. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol (2010) 11(2): 121–8. 10.1038/ni.1834 20023661 · DOI
  65. [69]Uno S Imagawa A Okita K Sayama K Moriwaki M Iwahashi H. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia (2007) 50(3): 596– 601. 10.1007/s00125-006-0569-9 17221211 · DOI
  66. [70]Diana J Simoni Y Furio L Beaudoin L Agerberth B Barrat F. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med (2013) 19(1): 65– 73. 10.1038/nm.3042 23242473 · DOI
  67. [71]Christianson SW Shultz LD Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes (1993) 42(1): 44– 55. 10.2337/diab.42.1.44 8093606 · DOI
  68. [72]Staeva TP Chatenoud L Insel R Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 62(1): 9– 17. 10.2337/db12-0562 23258904 PMC3526042 · DOI · Paper page
  69. [73]Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol (2020) 64: 1– 12. 10.1016/j.semcancer.2019.06.001 31181267 · DOI
  70. [74]Weiner LM Surana R Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 10(5): 317–27. 10.1038/nri2744 PMC3508064 20414205 · DOI
  71. [75]Bruno V Battaglia G Nicoletti F. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci (2011) 31 Suppl 3: 283–8. 10.1007/s10072-010-0382-6 20644974 · DOI
  72. [76]Tanaka T Hishitani Y Ogata A. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics (2014) 8: 141–53. 10.2147/BTT.S37509 PMC3984066 24741293 · DOI
  73. [77]Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 9(4): 271–85. 10.1038/nri2526 PMC2737409 19319144 · DOI
  74. [78]Kaplon H Muralidharan M Schneider Z Reichert JM. Antibodies to watch in 2020. MAbs (2020) 12(1): 1703531. 10.1080/19420862.2019.1703531 31847708 PMC6973335 · DOI
  75. [79]Hnasko RM Stanker LH. Hybridoma Technology. Methods Mol Biol (2015) 1318: 15– 28. 10.1007/978-1-4939-2742-5_2 26160560 · DOI
  76. [80]Hanack K Messerschmidt K Listek M. Antibodies and Selection of Monoclonal Antibodies. Adv Exp Med Biol (2016) 917: 11– 22. 10.1007/978-3-319-32805-8_2 27236550 · DOI
  77. [81]Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (1985) 228(4705): 1315–7. 10.1126/science.4001944 4001944 · DOI · Paper page
  78. [82]Cho W Fowler JD Furst EM. Targeted binding of the M13 bacteriophage to thiamethoxam organic crystals. Langmuir (2012) 28(14): 6013–20. 10.1021/la300522g 22404231 · DOI
  79. [83]Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 23(9): 1105–16. 10.1038/nbt1126 16151404 · DOI
  80. [84]Winter G Griffiths AD Hawkins RE Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol (1994) 12: 433–55. 10.1146/annurev.iy.12.040194.002245 8011287 · DOI · Paper page
  81. [85]Osbourn J Groves M Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods (2005) 36(1): 61–8. 10.1016/j.ymeth.2005.01.006 15848075 · DOI
  82. [86]Prassler J Thiel S Pracht C Polzer A Peters S Bauer M. HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol (2011) 413(1): 261–78. 10.1016/j.jmb.2011.08.012 21856311 · DOI
  83. [88]Azzazy HM Highsmith WE Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem (2002) 35(6): 425–45. 10.1016/s0009-9120(02)00343-0 12413604 · DOI
  84. [89]Imai S Mukai Y Takeda T Abe Y Nagano K Kamada H. Effect of protein properties on display efficiency using the M13 phage display system. Pharmazie (2008) 63(10): 760–4. 18972841
  85. [90]Jaffers GJ Fuller TC Cosimi AB Russell PS Winn HJ Colvin RB. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation (1986) 41(5): 572–8. 10.1097/00007890-198605000-00004 3085297 · DOI
  86. [91]Kimball JA Norman DJ Shield CF Schroeder TJ Lisi P Garovoy M. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol (1995) 3(3): 212–21. 10.1016/0966-3274(95)80027-1 8581409 · DOI
  87. [92]LoBuglio AF Wheeler RH Trang J Haynes A Rogers K Harvey EB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A (1989) 86(11): 4220–4. 10.1073/pnas.86.11.4220 PMC287422 2726771 · DOI
  88. [93]Hwang WY Foote J. Immunogenicity of engineered antibodies. Methods (2005) 36(1): 3– 10. 10.1016/j.ymeth.2005.01.001 15848070 · DOI
  89. [94]Baert F Noman M Vermeire S Van Assche G DH G Carbonez A. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med (2003) 348(7): 601–8. 10.1056/NEJMoa020888 12584368 · DOI
  90. [95]Jones PT Dear PH Foote J Neuberger MS Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321(6069): 522–5. 10.1038/321522a0 3713831 · DOI · Paper page
  91. [96]Carter P Presta L Gorman CM Ridgway JB Henner D Wong WL. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 89(10): 4285–9. 10.1073/pnas.89.10.4285 PMC49066 1350088 · DOI
  92. [97]Queen C Schneider WP Selick HE Payne PW Landolfi NF Duncan JF. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 86(24): 10029–33. 10.1073/pnas.86.24.10029 PMC298637 2513570 · DOI
  93. [98]Studnicka GM Soares S Better M Williams RE Nadell R Horwitz AH. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng (1994) 7(6): 805–14. 10.1093/protein/7.6.805 7937712 · DOI
  94. [99]de Haard H Kazemier B van der Bent A Oudshoorn P Boender P Arends JW. Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition. Immunotechnology (1999) 4(3-4): 203–15. 10.1016/s1380-2933(98)00021-9 10231090 · DOI
  95. [100]Makabe K Nakanishi T Tsumoto K Tanaka Y Kondo H Umetsu M. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem (2008) 283(2): 1156–66. 10.1074/jbc.M706190200 17947238 · DOI
  96. [101]Harding FA Stickler MM Razo J DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 2(3): 256–65. 10.4161/mabs.2.3.11641 PMC2881252 20400861 · DOI
  97. [102]Jakobovits A Amado RG Yang X Roskos L Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol (2007) 25(10): 1134–43. 10.1038/nbt1337 17921999 · DOI
  98. [103]Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol (2005) 23(9): 1117–25. 10.1038/nbt1135 16151405 · DOI · Paper page
  99. [104]Lonberg N Taylor LD Harding FA Trounstine M Higgins KM Schramm SR. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 368(6474): 856–9. 10.1038/368856a0 8159246 · DOI
  100. [105]Fishwild DM O’Donnell SL Bengoechea T Hudson DV Harding F Bernhard SL. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol (1996) 14(7): 845–51. 10.1038/nbt0796-845 9631008 · DOI
  101. [106]Dhimolea E. Canakinumab. MAbs (2010) 2(1): 3– 13. 10.4161/mabs.2.1.10328 20065636 PMC2828573 · DOI
  102. [107]Krueger GG Langley RG Leonardi C Yeilding N Guzzo C Wang Y. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 356(6): 580–92. 10.1056/NEJMoa062382 17287478 · DOI
  103. [108]Hirohata S. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)]. Nihon Rinsho (2007) 65(7): 1202–8. 17642233
  104. [109]Vidarsson G Dekkers G Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5: 520. 10.3389/fimmu.2014.00520 25368619 PMC4202688 · DOI · Paper page
  105. [110]Shields RL Lai J Keck R O’Connell LY Hong K Meng YG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 277(30): 26733–40. 10.1074/jbc.M202069200 11986321 · DOI · Paper page
  106. [111]Liu SD Chalouni C Young JC Junttila TT Sliwkowski MX Lowe JB. Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol Res (2015) 3(2): 173–83. 10.1158/2326-6066.CIR-14-0125 25387893 · DOI
  107. [112]Chatenoud L Ferran C Legendre C Thouard I Merite S Reuter A. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation (1990) 49(4): 697– 702. 10.1097/00007890-199004000-00009 2109379 · DOI
  108. [113]Ceuppens JL Bloemmen FJ Van Wauwe JP. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex. J Immunol (1985) 135(6): 3882–6. 2933454
  109. [114]Xu D Alegre ML Varga SS Rothermel AL Collins AM Pulito VL. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol (2000) 200(1): 16– 26. 10.1006/cimm.2000.1617 10716879 · DOI
  110. [115]Friend PJ Hale G Chatenoud L Rebello P Bradley J Thiru S. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 68(11): 1632–7. 10.1097/00007890-199912150-00005 10609938 · DOI
  111. [116]Hale G Rebello P Al Bakir I Bolam E Wiczling P Jusko WJ. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol (2010) 50(11): 1238–48. 10.1177/0091270009356299 20147616 · DOI
  112. [117]Tao MH Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1989) 143(8): 2595–601. 2507634
  113. [118]Roopenian DC Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7(9): 715–25. 10.1038/nri2155 17703228 · DOI · Paper page
  114. [119]Herold KC Gitelman SE Masharani U Hagopian W Bisikirska B Donaldson D. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes (2005) 54(6): 1763–9. 10.2337/diabetes.54.6.1763 PMC5315015 15919798 · DOI
  115. [120]Herold KC Hagopian W Auger JA Poumian-Ruiz E Taylor L Donaldson D. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 346(22): 1692–8. 10.1056/NEJMoa012864 12037148 · DOI · Paper page
  116. [121]Keymeulen B Candon S Fafi-Kremer S Ziegler A Leruez-Ville M Mathieu C. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2010) 115(6): 1145–55. 10.1182/blood-2009-02-204875 20007541 · DOI
  117. [123]Keymeulen B Vandemeulebroucke E Ziegler AG Mathieu C Kaufman L Hale G. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 352(25): 2598–608. 10.1056/NEJMoa043980 15972866 · DOI · Paper page
  118. [124]Reinherz EL Hussey RE Schlossman SF. A monoclonal antibody blocking human T cell function. Eur J Immunol (1980) 10(10): 758–62. 10.1002/eji.1830101006 6448746 · DOI
  119. [125]Herve P Flesch M Cahn JY Racadot E Plouvier E Lamy B. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. A pilot study in ten patients. Transplantation (1985) 39(2): 138–43. 10.1097/00007890-198502000-00006 3881852 · DOI
  120. [126]Chatenoud L Thervet E Primo J Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 91(1): 123–7. 10.1073/pnas.91.1.123 PMC42898 8278351 · DOI
  121. [127]Chatenoud L Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 7(8): 622–32. 10.1038/nri2134 17641665 · DOI
  122. [128]Belghith M Bluestone JA Barriot S Megret J Bach JF Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 9(9): 1202–8. 10.1038/nm924 12937416 · DOI
  123. [129]Perruche S Zhang P Liu Y Saas P Bluestone JA Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 14(5): 528–35. 10.1038/nm1749 18438416 · DOI
  124. [130]Carpenter PA Pavlovic S Tso JY Press OW Gooley T Yu XZ. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol (2000) 165(11): 6205–13. 10.4049/jimmunol.165.11.6205 11086054 · DOI
  125. [131]Yu XZ Anasetti C. Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab’)2. Transplantation (2000) 69(1): 104–12. 10.1097/00007890-200001150-00019 10653388 · DOI
  126. [132]Penaranda C Tang Q Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 187(4): 2015–22. 10.4049/jimmunol.1100713 PMC3150219 21742976 · DOI
  127. [133]Chatenoud L Primo J Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 158(6): 2947–54. 9058834
  128. [134]You S Leforban B Garcia C Bach JF Bluestone JA Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 104(15): 6335–40. 10.1073/pnas.0701171104 PMC1851030 17389382 · DOI
  129. [135]Keymeulen B Walter M Mathieu C Kaufman L Gorus F Hilbrands R. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 53(4): 614–23. 10.1007/s00125-009-1644-9 20225393 · DOI
  130. [137]Hagopian W Ferry RJ Jr. Sherry N Carlin D Bonvini E Johnson S. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes (2013) 62(11): 3901–8. 10.2337/db13-0236 PMC3806608 23801579 · DOI · Paper page
  131. [138]Waldron-Lynch F Henegariu O Deng S Preston-Hurlburt P Tooley J Flavell R. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med (2012) 4(118): 118ra12. 10.1126/scitranslmed.3003401 PMC4131554 22277969 · DOI
  132. [139]Long SA Thorpe J Herold KC Ehlers M Sanda S Lim N. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol (2017) 319: 3– 9. 10.1016/j.cellimm.2017.07.007 28844471 PMC5614459 · DOI
  133. [140]Long SA Thorpe J DeBerg HA Gersuk V Eddy J Harris KM. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol (2016) 1(5). 10.1126/sciimmunol.aai7793 PMC5486405 28664195 · DOI · Paper page
  134. [141]Wiedeman AE Muir VS Rosasco MG DeBerg HA Presnell S Haas B. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. J Clin Invest (2020) 130(1): 480–90. 10.1172/JCI126595 PMC6934185 31815738 · DOI · Paper page
  135. [142]Sherry N Hagopian W Ludvigsson J Jain SM Wahlen J Ferry RJ Jr.. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 378(9790): 487–97. 10.1016/S0140-6736(11)60931-8 PMC3191495 21719095 · DOI · Paper page
  136. [143]Aronson R Gottlieb PA Christiansen JS Donner TW Bosi E Bode BW. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care (2014) 37(10): 2746–54. 10.2337/dc13-0327 PMC4392937 25011949 · DOI
  137. [144]Ambery P Donner TW Biswas N Donaldson J Parkin J Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabetes Med (2014) 31(4): 399– 402. 10.1111/dme.12361 24236828 · DOI
  138. [145]Vlasakakis G Napolitano A Barnard R Brown K Bullman J Inman D. Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3epsilon mAb in new-onset type 1 diabetes mellitus patients. Br J Clin Pharmacol (2019) 85(4): 704–14. 10.1111/bcp.13842 PMC6422670 30566758 · DOI
  139. [146]Keymeulen B van Maurik A Inman D Oliveira J McLaughlin R Gittelman RM. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia (2020) 64(2): 313–24. 10.1007/s00125-020-05317-y PMC7801303 33145642 · DOI
  140. [149]Ochi H Abraham M Ishikawa H Frenkel D Yang K Basso AS. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 12(6): 627–35. 10.1038/nm1408 16715091 · DOI
  141. [150]Ilan Y Zigmond E Lalazar G Dembinsky A Ben Ya’acov A Hemed N. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol (2010) 30(1): 167–77. 10.1007/s10875-009-9323-7 PMC2822125 19756989 · DOI
  142. [151]Ishikawa H Ochi H Chen ML Frenkel D Maron R Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes (2007) 56(8): 2103–9. 10.2337/db06-1632 17456848 · DOI
  143. [152]Xiu Y Wong CP Bouaziz JD Hamaguchi Y Wang Y Pop SM. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol (2008) 180(5): 2863–75. 10.4049/jimmunol.180.5.2863 18292508 · DOI
  144. [153]Fiorina P Vergani A Dada S Jurewicz M Wong M Law K. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 57(11): 3013–24. 10.2337/db08-0420 PMC2570398 18689692 · DOI
  145. [154]Leete P Willcox A Krogvold L Dahl-Jorgensen K Foulis AK Richardson SJ. Differential Insulitic Profiles Determine the Extent of beta-Cell Destruction and the Age at Onset of Type 1 Diabetes. Diabetes (2016) 65(5): 1362–9. 10.2337/db15-1615 26858360 · DOI
  146. [155]Pescovitz MD Greenbaum CJ Bundy B Becker DJ Gitelman SE Goland R. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care (2014) 37(2): 453–9. 10.2337/dc13-0626 PMC3898764 24026563 · DOI
  147. [156]Chamberlain N Massad C Oe T Cantaert T Herold KC Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest (2016) 126(1): 282–7. 10.1172/JCI83840 PMC4701568 26642366 · DOI
  148. [157]Serreze DV Chapman HD Niens M Dunn R Kehry MR Driver JP. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes (2011) 60(11): 2914–21. 10.2337/db11-0705 PMC3198088 21926271 · DOI
  149. [158]Binder C Cvetkovski F Sellberg F Berg S Paternina Visbal H Sachs DH. CD2 Immunobiology. Front Immunol (2020) 11: 1090. 10.3389/fimmu.2020.01090 32582179 PMC7295915 · DOI
  150. [159]Sanders ME Makgoba MW Sharrow SO Stephany D Springer TA Young HA. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol (1988) 140(5): 1401–7. 2894392
  151. [160]Crawford K Gabuzda D Pantazopoulos V Xu J Clement C Reinherz E. Circulating CD2+ monocytes are dendritic cells. J Immunol (1999) 163(11): 5920–8. 10570278
  152. [161]Jenneck C Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manage (2007) 3(3): 411–20. PMC2386357 18488075
  153. [162]Cooper JC Morgan G Harding S Subramanyam M Majeau GR Moulder K. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol (2003) 33(3): 666–75. 10.1002/eji.200323586 12616487 · DOI
  154. [163]Rigby MR DiMeglio LA Rendell MS Felner EI Dostou JM Gitelman SE. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 1(4): 284–94. 10.1016/S2213-8587(13)70111-6 PMC3957186 24622414 · DOI
  155. [164]Rigby MR Harris KM Pinckney A DiMeglio LA Rendell MS Felner EI. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest (2015) 125(8): 3285–96. 10.1172/JCI81722 PMC4623571 26193635 · DOI
  156. [165]Chamian F Lowes MA Lin SL Lee E Kikuchi T Gilleaudeau P. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 102(6): 2075–80. 10.1073/pnas.0409569102 PMC545584 15671179 · DOI
  157. [166]Bruhns P Iannascoli B England P Mancardi DA Fernandez N Jorieux S. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113(16): 3716–25. 10.1182/blood-2008-09-179754 19018092 · DOI · Paper page
  158. [167]Brezski RJ Georgiou G. Immunoglobulin isotype knowledge and application to Fc engineering. Curr Opin Immunol (2016) 40: 62–9. 10.1016/j.coi.2016.03.002 27003675 · DOI
  159. [168]Sha S Agarabi C Brorson K Lee DY. Yoon S. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies. Trends Biotechnol (2016) 34(10): 835–46. 10.1016/j.tibtech.2016.02.013 27016033 · DOI
  160. [169]Brezski RJ Kinder M Grugan KD Soring KL Carton J Greenplate AR. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs (2014) 6(5): 1265–73. 10.4161/mabs.29825 PMC4623506 25517311 · DOI
  161. [170]Coomans de Brachene A Dos Santos RS Marroqui L Colli ML Marselli L Mirmira RG. IFN-alpha induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia (2018) 61(3): 636–40. 10.1007/s00125-017-4536-4 PMC6241216 29305625 · DOI · Paper page
  162. [171]Marroqui L Dos Santos RS Op de Beeck A Coomans de Brachene A Marselli L Marchetti P. Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia (2017) 60(4): 656–67. 10.1007/s00125-016-4201-3 28062922 · DOI · Paper page
  163. [172]Newby BN Brusko TM Zou B Atkinson MA Clare-Salzler M Mathews CE. Type 1 Interferons Potentiate Human CD8(+) T-Cell Cytotoxicity Through a STAT4- and Granzyme B-Dependent Pathway. Diabetes (2017) 66(12): 3061–71. 10.2337/db17-0106 PMC5697952 28877912 · DOI
  164. [173]Newby BN Mathews CE. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) (2017) 8: 232. 10.3389/fendo.2017.00232 28959234 PMC5604085 · DOI
  165. [174]Moran A Bundy B Becker DJ DiMeglio LA Gitelman SE Goland R. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 381(9881): 1905–15. 10.1016/S0140-6736(13)60023-9 PMC3827771 23562090 · DOI
  166. [175]Mastrandrea L Yu J Behrens T Buchlis J Albini C Fourtner S. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care (2009) 32(7): 1244–9. 10.2337/dc09-0054 PMC2699714 19366957 · DOI
  167. [177]Li Q Xu B Michie SA Rubins KH Schreriber RD McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 105(34): 12439–44. 10.1073/pnas.0806439105 PMC2527930 18716002 · DOI
  168. [178]Marro BS Ware BC Zak J de la Torre JC Rosen H Oldstone MB. Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-alpha signaling. Proc Natl Acad Sci U S A (2017) 114(14): 3708–13. 10.1073/pnas.1700878114 PMC5389329 28325871 · DOI
  169. [179]Debray-Sachs M Carnaud C Boitard C Cohen H Gresser I Bedossa P. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun (1991) 4(2): 237–48. 10.1016/0896-8411(91)90021-4 1909135 · DOI
  170. [180]Prud’homme GJ Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther (1999) 6(5): 771–7. 10.1038/sj.gt.3300879 10505100 · DOI
  171. [181]Calderon B Suri A Pan XO Mills JC Unanue ER. IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol (2008) 181(10): 6964–74. 10.4049/jimmunol.181.10.6964 PMC2653256 18981116 · DOI
  172. [182]Serreze DV Chapman HD Post CM Johnson EA Suarez-Pinzon WL Rabinovitch A. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol (2001) 166(2): 1352–9. 10.4049/jimmunol.166.2.1352 11145720 · DOI
  173. [183]Serreze DV Post CM Chapman HD Johnson EA Lu B Rothman PB. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes (2000) 49(12): 2007–11. 10.2337/diabetes.49.12.2007 11118001 · DOI
  174. [184]Hultgren B Huang X Dybdal N Stewart TA. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes (1996) 45(6): 812–7. 10.2337/diab.45.6.812 8635658 · DOI
  175. [185]Fujihira K Nagata M Moriyama H Yasuda H Arisawa K Nakayama M. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes (2000) 49(12): 1998– 2006. 10.2337/diabetes.49.12.1998 11118000 · DOI
  176. [186]Wu X Tian J Wang S. Insight Into Non-Pathogenic Th17 Cells in Autoimmune Diseases. Front Immunol (2018) 9: 1112. 10.3389/fimmu.2018.01112 29892286 PMC5985293 · DOI
  177. [187]Sutherland AP Van Belle T Wurster AL Suto A Michaud M Zhang D. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes (2009) 58(5): 1144–55. 10.2337/db08-0882 PMC2671036 19208913 · DOI
  178. [188]McGuire HM Walters S Vogelzang A Lee CM Webster KE Sprent J. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes (2011) 60(3): 867–75. 10.2337/db10-1157 PMC3046847 21357471 · DOI
  179. [189]Yang XO Nurieva R Martinez GJ Kang HS Chung Y Pappu BP. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 29(1): 44– 56. 10.1016/j.immuni.2008.05.007 18585065 PMC2630532 · DOI
  180. [190]Astry B Venkatesha SH Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. Cytokine (2015) 74(1): 54– 61. 10.1016/j.cyto.2014.11.020 25595306 PMC4457562 · DOI
  181. [191]Tubo NJ Jenkins MK. TCR signal quantity and quality in CD4(+) T cell differentiation. Trends Immunol (2014) 35(12): 591–6. 10.1016/j.it.2014.09.008 PMC4406772 25457838 · DOI
  182. [192]Bhattacharyya ND Feng CG. Regulation of T Helper Cell Fate by TCR Signal Strength. Front Immunol (2020) 11: 624: 624. 10.3389/fimmu.2020.00624 32508803 PMC7248325 · DOI
  183. [193]van Panhuys N. TCR Signal Strength Alters T-DC Activation and Interaction Times and Directs the Outcome of Differentiation. Front Immunol (2016) 7: 6: 6. 10.3389/fimmu.2016.00006 26834747 PMC4725058 · DOI
  184. [195]Orban T Bundy B Becker DJ Dimeglio LA Gitelman SE Goland R. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2014) 37(4): 1069–75. 10.2337/dc13-0604 PMC3964491 24296850 · DOI
  185. [196]Martin AJ Clark M Gojanovich G Manzoor F Miller K Kline DE. Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues. JCI Insight (2016) 1(17): e87636. 10.1172/jci.insight.87636 27777971 PMC5070954 · DOI
  186. [197]Morillon YM,2 Lessey-Morillon EC Clark M Zhang R Wang B Burridge K. Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration. J Immunol (2016) 197(9): 3504–11. 10.4049/jimmunol.1501600 PMC5101163 27694496 · DOI
  187. [198]Yi Z Diz R Martin AJ Morillon YM Kline DE Li L. Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes (2012) 61(11): 2871–80. 10.2337/db12-0098 PMC3478559 22751694 · DOI
  188. [199]Phillips JM Parish NM Raine T Bland C Sawyer Y De La Pena H. Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations. Rev Diabetes Stud (2009) 6(2): 97– 103. 10.1900/RDS.2009.6.97 PMC2779016 19806239 · DOI
  189. [200]Phillips JM Harach SZ Parish NM Fehervari Z Haskins K Cooke A. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells. J Immunol (2000) 165(4): 1949–55. 10.4049/jimmunol.165.4.1949 10925277 · DOI
  190. [201]Konig M Rharbaoui F Aigner S Dalken B Schuttrumpf J. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol (2016) 7: 11. 10.3389/fimmu.2016.00011 26834751 PMC4724712 · DOI
  191. [202]Zhang L Crawford F Yu L Michels A Nakayama M Davidson HW. Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A (2014) 111(7): 2656–61. 10.1073/pnas.1323436111 PMC3932899 24550292 · DOI
  192. [203]Lee LF Logronio K Tu GH Zhai W Ni I Mei L. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 109(31): 12674–9. 10.1073/pnas.1203795109 PMC3412026 22733769 · DOI
  193. [204]Penaranda C Kuswanto W Hofmann J Kenefeck R Narendran P Walker LS. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 109(31): 12668–73. 10.1073/pnas.1203692109 PMC3411948 22733744 · DOI
  194. [205]Herold KC Bucktrout SL Wang X Bode BW Gitelman SE Gottlieb PA. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight (2019) 4(24). 10.1172/jci.insight.126054 PMC6975260 31852846 · DOI
  195. [206]Yossef R Gur C Shemesh A Guttman O Hadad U Nedvetzki S. Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes. PloS One (2015) 10(2): e0118936. 10.1371/journal.pone.0118936 25719382 PMC4342013 · DOI
  196. [207]Berhani O Glasner A Kahlon S Duev-Cohen A Yamin R Horwitz E. Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research. Eur J Immunol (2019) 49(2): 228–41. 10.1002/eji.201847611 30536875 · DOI
  197. [208]Gur C Enk J Kassem SA Suissa Y Magenheim J Stolovich-Rain M. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol (2011) 187(6): 3096–103. 10.4049/jimmunol.1101269 21849674 · DOI
  198. [209]Sandor AM Jacobelli J Friedman RS. Immune cell trafficking to the islets during type 1 diabetes. Clin Exp Immunol (2019) 198(3): 314–25. 10.1111/cei.13353 PMC6857188 31343073 · DOI
  199. [210]Martin S van den Engel NK Vinke A Heidenthal E Schulte B Kolb H. Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J Autoimmun (2001) 17(2): 109–17. 10.1006/jaut.2001.0526 11591119 · DOI
  200. [211]Yang XD Michie SA Tisch R Karin N Steinman L McDevitt HO. A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 91(26): 12604–8. 10.1073/pnas.91.26.12604 PMC45487 7528925 · DOI

200 of 225 shown

Cited by

Sorted by citations

Authors
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Tisch, Roland M.
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2021-02-18
Volume
11
Pages
624568-624568
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2020.624568
PMC
PMC7930374
OpenAlex
W3129355564
Cited by
44
References
9
Citations by year
2026: 6 · 2025: 8 · 2024: 11 · 2023: 12 · 2022: 4 · 2021: 2 · 2019: 1
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Foundation for the National Institutes of Health
  • National Institutes of Health
  • American Diabetes Association Research Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords
type 1 diabetes, monoclonal antibodies, antibody-based immunotherapy, T cell-mediated autoimmunity, islet autoimmunity, cell depletion, T cell depletion, remission induction
MeSH terms
Antibodies, Monoclonal, Diabetes Mellitus, Type 1, Humans, Immunotherapy, Lymphocyte Depletion, T-Lymphocytes, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review